NBTX

Nanobiotix S.A.

6.53 USD
-0.72 (-9.93%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nanobiotix S.A. stock is up 20.7% since 30 days ago. The next earnings date is Sep 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 May’s closed higher than April.

About Nanobiotix S.A.

Nanobiotix S.A. focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer and non-small cell lung cancer.